Objective. This study aimed at analyzing the association between recurrent pregnancy loss (RPL) and factor V G1691A (FVL), prothrombin G20210 (FII); and MTHFR C677T (MTHFR) in Palestinian women. Method. We studied 329 Palestinian women with RPL and/or stillbirth (SB); and compared them to 402 healthy reproductive Palestinian women. Cases and controls were tested for the above mutations. Odds ratio (OR) at confidence interval (CI) of 95% was used as a measure of association between the mutations and RPL. Results. Our statistical analysis showed a slightly increased association, which was not significant between FVL and RPL (OR？1.32, 95%？CI？0.90–1.94), and no association between FII (OR？0.84, 95%？CI？0.38–1.92), MTHFR (OR？0.58, 95% CI？0.32–1.03), and RPL. Further analysis of RPL subgroups revealed an association between FVL and first-trimester loss (OR？1.33, 95%？CI？0.892–1.989), and second-trimester loss (OR？1.13, 95%？CI？0.480–2.426), both were not statistically significant. Furthermore, the only statistically significant association was between FVL and SB (OR？2.0, 95%？CI？1.05–3.70). Conclusion. Our analysis had failed to find a significant association between FVL, FII, MTHFR; and RPL in either the first or second trimester. FVL was significantly associated with fetal loss if the loss was a stillbirth. 1. Introduction Molecular studies of coagulation disorders have led to the discovery of an increasing number of mutations in the genes of the factors of coagulation, termed inherited thrombophilia (IT). The most important of this group are factor V gene Leiden mutation G1691A (FVL), prothrombin G20210 (FII), homozygosity for the thermolabile of methyltetrahydrofolate reductase deficiency C677T (MTHFR), antithrombin deficiency, protein C deficiency, and protein S deficiency [1–7]. These conditions affect coagulation cascade at different stages; increasing the potential for thromboembolic diseases (TE) [4, 7]. The importance of IT in obstetrics stems from being partly responsible for up to half of maternal venous TE [2, 5], which is one of the direct leading causes of maternal mortality [2, 5, 8]. While the relationship of IT to TE is not disputed and has been confirmed by a number of studies [4, 7], the evidence is conflicting regarding the association with pregnancy complications [1, 5, 6, 8–11]. A delicate balance between coagulant and anticoagulant factors is needed to achieve a successful pregnancy [12]. A balanced system maintains the blood flow to the feto-maternal exchange unit and promotes trophoblastic proliferation [2, 5, 6]. The hypercoagulable
References
[1]
G. Lissalde-Lavigne, E. Cochery-Nouvellon, E. Mercier et al., “The association between hereditary thrombophilias and pregnancy loss,” Haematologica, vol. 90, no. 9, pp. 1223–1230, 2005.
[2]
I. A. Greer, “Thrombophilia: implications for pregnancy outcome,” Thrombosis Research, vol. 109, no. 2-3, pp. 73–81, 2003.
[3]
G. Kovalevsky, C. R. Gracia, J. A. Berlin, M. D. Sammel, and K. T. Barnhart, “Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis,” Archives of Internal Medicine, vol. 164, no. 5, pp. 558–563, 2004.
[4]
C. J. Lockwood and K. A. Bauer, “Inherited thrombophilias in pregnancy,” UpToDate, 2008.
[5]
C. J. Lockwood, Ed., “Inherited thrombophilias in pregnant patients: detection and treatment paradigm,” Obstetrics and Gynecology, vol. 99, no. 2, pp. 333–341, 2002.
[6]
M. A. Rodger, M. Paidas, M. Claire et al., “Inherited thrombophilia and pregnancy complications revisited,” Obstetrics and Gynecology, vol. 112, no. 2, part 1, pp. 320–324, 2008.
[7]
A. Eldor, “Thrombophilia, thrombosis and pregnancy,” Thrombosis and Haemostasis, vol. 86, no. 1, pp. 104–111, 2001.
[8]
W. H. Kutteh and D. A. Triplett, “Thrombophilias and recurrent pregnancy loss,” Seminars in Reproductive Medicine, vol. 24, no. 1, pp. 54–65, 2006.
[9]
G. Sottilotta, V. Oriana, C. Latella et al., “Genetic prothrombotic risk factors in women with unexplained pregnancy loss,” Thrombosis Research, vol. 117, no. 6, pp. 681–684, 2006.
[10]
E. Rey, S. R. Kahn, M. David, and I. Shrier, “Thrombophilic disorders and fetal loss: a meta-analysis,” The Lancet, vol. 361, no. 9361, pp. 901–908, 2003.
[11]
O. B. Christiansen, H. S. Nielsen, A. Kolte, and A. T. Pedersen, “Research methodology and epidemiology of relevance in recurrent pregnancy loss,” Seminars in Reproductive Medicine, vol. 24, no. 1, pp. 5–16, 2006.
[12]
C. Y. Vossen, F. E. Preston, J. Conard et al., “Hereditary thrombophilia and fetal loss: a prospective follow-up study,” Journal of Thrombosis and Haemostasis, vol. 2, no. 4, pp. 592–596, 2004.
[13]
D. W. Branch, R. M. Silver, J. L. Blackwell, J. C. Reading, and J. R. Scott, “Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience,” Obstetrics and Gynecology, vol. 80, no. 4, pp. 614–620, 1992.
[14]
S. A. Miller, D. D. Dykes, and H. F. Polesky, “A simple salting out procedure for extracting DNA from human nucleated cells,” Nucleic Acids Research, vol. 16, no. 3, p. 1215, 1988.
[15]
C. D. K. Bottema, G. Sarkar, J. D. Cassady, S. Ii, C. M. Dutton, and S. S. Sommer, “Polymerase chain reaction amplification of specific alleles: a general method of detection of mutations, polymorphisms, and haplotypes,” Methods in Enzymology, vol. 218, pp. 388–402, 1993.
[16]
R. Elles and R. Mountford, Molecular Diagnosis of Genetic Diseases, Humana Press, Totowa, NJ, USA, 2nd edition, 2004.
[17]
Palestinian Central Bureau of Statistics, http://www.pcbs.gov.ps/Portals/_pcbs/health/hl00_n04.aspx.
[18]
E. Rosen, P. Renbaum, J. Heyd, and E. Levy-Lahad, “High frequency of factor V Leiden in a population of Israeli Arabs,” Thrombosis and Haemostasis, vol. 82, no. 6, p. 1768, 1999.
[19]
A. Awidi, M. Shannak, A. Bseiso et al., “High prevalence of factor V Leiden in healthy Jordanian Arabs,” Thrombosis and Haemostasis, vol. 81, no. 4, pp. 582–584, 1999.
[20]
S. S. Eid and G. Rihani, “Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in 200 healthy Jordanians,” Clinical Laboratory Science, vol. 17, no. 4, pp. 200–202, 2004.
[21]
L. F. Zahed, R. F. Rayes, R. A. Mahfouz, A. T. Taher, H. H. Maarouf, and A. H. Nassar, “Prevalence of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase mutations in womenwith adverse pregnancy outcomes in Lebanon,” American Journal of Obstetrics and Gynecology, vol. 195, no. 4, pp. 1114–1118, 2006.
[22]
W. Y. Almawi, S. H. Keleshian, L. Borgi et al., “Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs,” Journal of Thrombosis and Thrombolysis, vol. 20, no. 3, pp. 163–168, 2005.
[23]
N. Irani-Hakime, H. Tamim, R. Kreidy, and W. Y. Almawi, “The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese,” American Journal of Hematology, vol. 65, no. 1, pp. 45–49, 2000.
[24]
K. Angelopoulou, A. Nicolaides, and C. C. Deltas, “Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population,” Clinical and Applied Thrombosis/Hemostasis, vol. 6, no. 2, pp. 104–107, 2000.
[25]
V. De Stefano, P. Chiusolo, K. Paciaroni, and G. Leone, “Epidemiology of factor V leiden: clinical implications,” Seminars in Thrombosis and Hemostasis, vol. 24, no. 4, pp. 367–379, 1998.
[26]
S. Assaf and M. Khawaja, “Consanguinity trends and correlates in the Palestinian Territories,” Journal of Biosocial Science, vol. 41, no. 1, pp. 107–124, 2009.
[27]
M. M. Mokhtar and M. M. Abdel-Fattah, “Consanguinity and advanced maternal age as risk factors for reproductive losses in Alexandria, Egypt,” European Journal of Epidemiology, vol. 17, no. 6, pp. 559–565, 2001.
[28]
M. F. Reznikoff-Etiévant, V. Cayol, B. Carbonne, A. Robert, F. Coulet, and J. Milliez, “Factor V Leiden and G20210A prothrombin mutations are risk factors for very early recurrent miscarriage,” British Journal of Obstetrics and Gynaecology, vol. 108, no. 12, pp. 1251–1254, 2001.
[29]
Z. J. Foka, A. F. Lambropoulos, H. Saravelos, et al., “Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages,” Human Reproduction, vol. 15, no. 2, pp. 458–462, 2000.
[30]
E. Grandone, M. Margaglione, D. Colaizzo et al., “Factor V Leiden is associated with repeated and recurrent unexplained fetal losses,” Thrombosis and Haemostasis, vol. 77, no. 5, pp. 822–824, 1997.
[31]
F. E. Preston, F. R. Rosendaal, I. D. Walker et al., “Increased fetal loss in women with heritable thrombophilia,” The Lancet, vol. 348, no. 9032, pp. 913–916, 1996.
[32]
J.-C. Gris, S. Ripart-Neveu, C. Maugard et al., “Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study,” Thrombosis and Haemostasis, vol. 77, no. 6, pp. 1096–1103, 1997.
[33]
B. Brenner, G. Sarig, Z. Weiner, J. Younis, Z. Blumenfeld, and N. Lanir, “Thrombophilic polymorphisms are common in women with fetal loss without apparent cause,” Thrombosis and Haemostasis, vol. 82, no. 1, pp. 6–9, 1999.
[34]
Z. R. Holmes, L. Regan, I. Chilcott, and H. Cohen, “The C677T MTHFR gene mutation is not predictive of risk for recurrent fetal loss,” British Journal of Haematology, vol. 105, no. 1, pp. 98–101, 1999.
